A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2015

At a glance

  • Drugs Tipifarnib (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 May 2013 Planned end date changed from 1 Dec 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 22 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top